DexComDXCM
DXCM
About: Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Employees: 9,600
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
62% more first-time investments, than exits
New positions opened: 186 | Existing positions closed: 115
43% more call options, than puts
Call options by funds: $716M | Put options by funds: $499M
16% more capital invested
Capital invested by funds: $24B [Q3] → $27.8B (+$3.79B) [Q4]
6% more funds holding
Funds holding: 872 [Q3] → 923 (+51) [Q4]
0.19% less ownership
Funds ownership: 89.32% [Q3] → 89.13% (-0.19%) [Q4]
2% less repeat investments, than reductions
Existing positions increased: 322 | Existing positions reduced: 329
22% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 7 (-2) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$82
22%
upside
Avg. target
$102
51%
upside
High target
$115
71%
upside
5 analyst ratings
4 positive
80%
1 neutral
20%
0 negative
0%
Citigroup Joanne Wuensch 43% 1-year accuracy 22 / 51 met price target | 54%upside $104 | Buy Maintained | 4 Mar 2025 |
Canaccord Genuity William Plovanic 46% 1-year accuracy 22 / 48 met price target | 53%upside $103 | Buy Maintained | 14 Feb 2025 |
Morgan Stanley Patrick Wood 50% 1-year accuracy 6 / 12 met price target | 22%upside $82 | Equal-Weight Maintained | 14 Feb 2025 |
Redburn Atlantic Issie Kirby 33% 1-year accuracy 1 / 3 met price target | 71%upside $115 | Buy Upgraded | 3 Feb 2025 |
Baird Jeff Johnson 39% 1-year accuracy 11 / 28 met price target | 54%upside $104 | Outperform Upgraded | 16 Jan 2025 |
Financial journalist opinion
Based on 16 articles about DXCM published over the past 30 days
Neutral
Business Wire
8 hours ago
Government of Saskatchewan Expands Public Coverage for Dexcom Continuous Glucose Monitoring Systems
BURNABY, British Columbia--(BUSINESS WIRE)--The Government of Saskatchewan expands public coverage for Dexcom Continuous Glucose Monitoring Systems.
Negative
Market Watch
23 hours ago
These 20 worst-performing stocks in the S&P 500 sank 17% or more in March
Stocks turned higher on Monday afternoon to finish March on a positive note. Still, the S&P 500 ended with a 5.8% decline for March, with 69% of component stocks down for the month.
Positive
Zacks Investment Research
1 day ago
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.
Negative
Zacks Investment Research
5 days ago
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 Approval
DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The company response is inadequate.
Positive
Zacks Investment Research
6 days ago
DXCM Stock Gains Following New Data on Upcoming G7 CGM Sensor
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost competitive advantage.
Neutral
Business Wire
1 week ago
Dexcom Appoints Jon Coleman as Chief Commercial Officer
SAN DIEGO--(BUSINESS WIRE)--Dexcom Appoints Jon Coleman as Chief Commercial Officer.
Neutral
Business Wire
1 week ago
Nanowear Announces Continuous Glucose Monitoring (CGM) Licensing and Data Partnership With Dexcom
NEW YORK--(BUSINESS WIRE)--Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose data from Dexcom G7 Continuous Glucose Monitoring Systems (CGM) time synchronously alongside Nanowear's previously FDA cleared cardiovascular biomarkers. The continuous combination of glucose readings, blood pressure, ECGs, lung volume, respiration and hemodynamics offer unpre.
Positive
The Motley Fool
1 week ago
Nasdaq Sell-Off: 2 Brilliant Stocks to Buy No Matter What the Market Does Next
Equity markets started 2025 pretty well, but things haven't been so rosy in the past couple of months. The tech-heavy Nasdaq Composite index is down by 8% since the beginning of the year as I write this.
Neutral
Business Wire
1 week ago
Dexcom Report Unveiled at ATTD 2025 Reveals HCPs Favour Tech Over Medication for Future of Type 2 Care
EDINBURGH, Scotland & SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." The report surveyed over 2,500 people, made up of individuals with Type 2 diabetes and healthcare professionals, from Germany, Italy, the Netherlands, Saudi Arabia, Spain and the United Kingdom. The findings provide valuable in.
Negative
Zacks Investment Research
2 weeks ago
DexCom CGM Sensor Sales to Continue Despite FDA Warning Letter
DXCM faces an FDA warning over manufacturing issues, but operations remain unaffected. However, supply-chain risks and rising competition pose challenges.
Charts implemented using Lightweight Charts™